Quadrant Biosciences Offers Common Shares of the Company

Quadrant Biosciences Offers Common Shares of the Company

We’re excited to share a new opportunity for investors looking to help improve the lives of  families across the country. 

Quadrant Biosciences is now offering common shares to the general public through the equity crowdfunding platform, Wefunder

This campaign is the first time Quadrant is offering shares to the public at large, however we’ve previously raised over $32 million through private sales of our common shares to accredited investors. The offering is priced at $3/share, with a minimum investment of $300. 

So why consider investing in Quadrant Biosciences?

 

The world’s first epigenetic test for autism – Clarifi ASD™

In December, our company commercially released Clarifi ASD, the first of its kind epigenetic saliva test to aid the diagnosis of autism. The test is available to children 18 months through six years of age with a clinical suspicion of ASD.

We collaborated with researchers from SUNY Upstate Medical University and Penn State College of Medicine to create this novel biological test. Now, we are currently applying this same science to the development of a saliva diagnostic test for the COVID 19 virus.

 

A robust pipeline of future products

One of the most exciting things that we’ve discovered is that integration of epigenetics and the microbiome can aid in the early diagnosis of  a number of other neurological conditions. 

As a result, the Clarifi diagnostic platform has applications for many other health issues. 

Diagnostic products for early-stage Parkinson’s disease, mTBI/concussion, anorexia, and schizophrenia are currently in development. Several peer-reviewed research papers have already been published on the application of this approach to these worldwide neurological health concerns.

“Our collaborative research with SUNY Upstate Medical and Penn State College of Medicine has shown that the same approach we used for developing the Clarifi autism saliva test – evaluating epigenetic molecules found in the saliva – is demonstrating similar diagnostic utility for other neurological diseases such as Parkinson’s Disease and Concussion Injuries. It is exciting and extremely gratifying to be on the forefront of these life-changing discoveries,” explains Founder and CEO of Quadrant Biosciences, Rich Uhlig.

 

An experienced team

We’ve assembled a seasoned management team, including our Founder, Rich Uhlig, the former CEO of Morgan Stanley Bank.

In addition, our medical advisory board is composed of recognized leaders in the area of autism and epigenetic research. We’ve also partnered with top research and support organizations to provide families and clinicians with more resources during and after the diagnostic process.

 

Interested in Investing in Quadrant Biosciences?

Interested investors can learn more about our company and the investment opportunity by clicking here. If you have any questions, contact us through our Wefunder page. A member of our Quadrant Team will get back to you quickly.

 


AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT. YOU MAY OBTAIN A COPY OF THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT FROM HERE.  YOU SHOULD READ THE OFFERING CIRCULAR  BEFORE MAKING ANY INVESTMENT.
See the NCPS Offerings Disclosure here.
Securities offered through North Capital Private Securities, member FINRA/SIPC.  

Securities offered through North Capital Private Securities, member FINRA/SIPC.  Not an offering of securities. Non-registered investments are highly illiquid and risky and are not suitable for all investors. Past performance is not indicative of future results. This message is not an offer to sell or the solicitation of an offer to buy any security, which only can be made through official offering documents that contain important information about risks, fees and expenses. We suggest that you consult with a financial advisor, attorney, accountant, and any other professional that can help you to understand and assess the risks associated with any investment opportunity. Securities offered through North Capital Private Securities, member FINRA/SIPC.
THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS